S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands

Nuwellis (CHFS) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

CHFS vs. HSDT, BSGM, NUWE, TIVC, NDRA, GOVX, SNPX, ALBT, PEAR, and NAVB

Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include Helius Medical Technologies (HSDT), BioSig Technologies (BSGM), Nuwellis (NUWE), Tivic Health Systems (TIVC), ENDRA Life Sciences (NDRA), GeoVax Labs (GOVX), Synaptogenix (SNPX), Avalon GloboCare (ALBT), Pear Therapeutics (PEAR), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "medical" sector.

Nuwellis vs.

Nuwellis (NASDAQ:CHFS) and Helius Medical Technologies (NASDAQ:HSDT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, Helius Medical Technologies had 2 more articles in the media than Nuwellis. MarketBeat recorded 2 mentions for Helius Medical Technologies and 0 mentions for Nuwellis. Helius Medical Technologies' average media sentiment score of 0.30 beat Nuwellis' score of 0.00 indicating that Helius Medical Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Nuwellis Neutral
Helius Medical Technologies Neutral

Helius Medical Technologies has lower revenue, but higher earnings than Nuwellis. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuwellis$5.51M0.65-$18.11M-$279.280.00
Helius Medical Technologies$790K4.10-$14.07M-$21.49-0.21

Helius Medical Technologies has a consensus price target of $85.00, suggesting a potential upside of 1,764.04%. Given Helius Medical Technologies' higher possible upside, analysts plainly believe Helius Medical Technologies is more favorable than Nuwellis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuwellis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Helius Medical Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Nuwellis has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.

Nuwellis received 305 more outperform votes than Helius Medical Technologies when rated by MarketBeat users. Likewise, 69.53% of users gave Nuwellis an outperform vote while only 55.88% of users gave Helius Medical Technologies an outperform vote.

CompanyUnderperformOutperform
NuwellisOutperform Votes
324
69.53%
Underperform Votes
142
30.47%
Helius Medical TechnologiesOutperform Votes
19
55.88%
Underperform Votes
15
44.12%

65.1% of Nuwellis shares are held by institutional investors. 0.6% of Nuwellis shares are held by company insiders. Comparatively, 7.3% of Helius Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nuwellis has a net margin of -254.26% compared to Helius Medical Technologies' net margin of -1,602.40%. Nuwellis' return on equity of -173.61% beat Helius Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Nuwellis-254.26% -173.61% -131.01%
Helius Medical Technologies -1,602.40%-232.74%-100.23%

Summary

Nuwellis and Helius Medical Technologies tied by winning 8 of the 16 factors compared between the two stocks.


Get Nuwellis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHFS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHFS vs. The Competition

MetricNuwellisElectromedical Equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$3.58M$3.13B$4.90B$7.51B
Dividend YieldN/A1.76%2.87%3.87%
P/E Ratio-0.0112.69240.0016.68
Price / Sales0.6569.703,150.78301.28
Price / CashN/A51.8595.4255.16
Price / Book0.053.504.454.54
Net Income-$18.11M$87.84M$114.12M$211.48M

Nuwellis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HSDT
Helius Medical Technologies
1.1414 of 5 stars
$5.83
-0.2%
$85.00
+1,358.0%
-66.7%$4.14M$790,000.00-0.2726Short Interest ↑
BSGM
BioSig Technologies
0 of 5 stars
$0.52
-16.1%
N/A-94.3%$4.69M$290,000.00-0.1147Short Interest ↑
High Trading Volume
NUWE
Nuwellis
0.3629 of 5 stars
$0.70
+16.6%
N/A-92.4%$2.29M$8.54M-0.0470Short Interest ↑
Gap Up
High Trading Volume
TIVC
Tivic Health Systems
0 of 5 stars
$1.24
flat
N/A-91.1%$1.82M$1.23M-0.0316Short Interest ↑
Gap Down
NDRA
ENDRA Life Sciences
1.8462 of 5 stars
$1.12
-2.6%
$9.00
+703.6%
-71.3%$12.37MN/A-0.4021Short Interest ↑
Gap Down
GOVX
GeoVax Labs
2.9516 of 5 stars
$2.36
+0.4%
$90.00
+3,713.6%
-74.6%$4.20M$80,000.00-0.1814Short Interest ↑
SNPX
Synaptogenix
0 of 5 stars
$0.21
+17.1%
N/A-79.7%$4.19MN/A-0.205Short Interest ↑
ALBT
Avalon GloboCare
0 of 5 stars
$0.39
+2.6%
N/A-83.1%$4.29M$1.23M0.005News Coverage
PEAR
Pear Therapeutics
0 of 5 stars
N/AN/AN/A$4.17M$12.69M-0.13300
NAVB
Navidea Biopharmaceuticals
0 of 5 stars
$0.04
flat
N/A-85.5%$4.15M$70,000.00-0.6911

Related Companies and Tools

This page (NASDAQ:CHFS) was last updated on 3/1/2024 by MarketBeat.com Staff